Virtual
Inflammatory Bowel Diseases Pocket Guide
©”The circle Bridge” by Maria Eklind
16th Congress of ECCO Virtual July 2-3 & 8-10, 2021
www.ecco-ibd.eu ECCO’21 Virtual Congress | About ECCO
Key Dates June 28, 2021 ECCO‘21 Virtual Congress Platform opens July 2-3, 2021 Educational Programme July 8-10, 2021 16th Congress of ECCO 2021: Scientific Programme ECCO IBD APP ECCO Congress Office July 2, 2021 07:00 - 19:00 CEST Download July 3, 2021 07:00 - 17:00 CEST now! July 5-7, 2021 09:00 - 17:00 CEST July 8, 2021 07:00 - 19:00 CEST July 9, 2021 07:00 - 19:00 CEST July 10, 2021 07:00 - 16:00 CEST
About ECCO
ECCO strives for optimisation of care for patients with IBD in all aspects. As part of this mission ECCO adopts and further all efforts that lead to an improvement of the use of current therapies and procedures. Main aims include the development of guidelines with highest possible methodology and content quality and joint efforts to define better and more valid outcome parameters for the therapy of IBD. Further aspects of the mission include the promotion of specialist, postgraduate education in IBD, as well as scientific projects in IBD. Such promotion can include intellectual input, funding and joint The World of ECCO training using an ECCO defined curriculum. ECCO’s visibility will always be as an organisation and not as the individuals making up in your pocket ECCO. With all its activities the name of ECCO will stand in the world Features and Benefits: of gastroenterology for the highest possible level in quality and full • Listen to Audio Podcasts and impartiality in the results. watch Talking Heads on the go • Discover the e-Guide ECCO Office • Access ECCO News at any time • Find more ECCO Initiatives at one glance Ungargasse 6/13 • Stay up-to-date in the IBD World 1030 Vienna, Austria Phone: +43-(0)1-710 22 42 • Explore the ECCO’21 Congress Fax: +43-(0)1-710 22 42-001 E-Mail: [email protected] Available in App Stores free of charge: Web: www.ecco-ibd.eu
2 16th Congress of ECCO - European Crohn‘s and Colitis Organisation Scientific programme day by day “IBD precise”
10: Are we safer with biologics or 14:25 - 14:40 small-molecules? “IBD precise” E. Louis, Liège, Belgium 11: OP05: Association of ultra-processed food intake with risk of Inflammatory Bowel Disease from the Thursday, July 8, 2021 14:40 - 14:50 prospective urban rural epidemiology (PURE) study: Scientific programme day by day A prospective cohort study N. Narula, Hamilton, Canada Industry Sponsored Satellite Symposia 12: OP06: 5-aminosalicylates are not associated 11:00 - 12:00 1a, 1b &1c with adverse outcomes in Inflammatory Bowel 1: Opening 14:50 - 15:00 Disease patients with COVID-19: Analysis from an 12:15 - 12:30 L. Peyrin-Biroulet, Vandœuvre-Lès-Nancy, France international registry R. Ungaro, New York, United States Scientific Session 1: Sophisticated strategies within reach 13: Are surgical interventions really more harmful 12:30 - 13:45 P. Irving, London, United Kingdom 15:00 - 15:15 than medical treatment? S. Vermeire, Leuven, Belgium O. Faiz, Harrow, United Kingdom 2: Head to head trials 15:15- 15:30 Break 12:30 - 12:45 S. Ghosh, Cork, Ireland Scientific Session 3: Hot and (almost) happening 3: OP01: Comparison of fecal transplantation, 15:30 - 16:35 J. Burisch, Hvidovre, Denmark fecal transplantation with the novel UC diet or C. Maaser, Lüneburg, Germany the UC diet alone for Refractory Mild to Moderate 15:30 - 15:45 14: How machine learning will affect IBD treatment 12:45 - 12:55 Active Ulcerative Colitis: The CRAFT UC randomized S. Ennis, Southampton, United Kingdom controlled trial 15: Artificial intelligence: A strategic alliance A. Levine, Holon, Israel 15:45 - 16:00 between the machine and the endoscopist 4: Switching from IV to SC: Benefits beyond merely P. Bossuyt, Bonheiden, Belgium 12:55 - 13:10 convenience? 16: OP07: Artificial intelligence surpasses S. Schreiber, Kiel, Germany 16:00 - 16:10 gastrointestinal experts in the classification of 5: OP02: Ustekinumab versus adalimumab for endoscopic severity among Ulcerative Colitis B. Lo, Hvidovre, Denmark 13:10 - 13:20 induction and maintenance therapy in Moderate-to- Severe Crohn’s Disease: The SEAVUE study 17: OP08: Automatic detection of enteric ulcers and P. Irving, London, United Kingdom 16:10 - 16:20 erosions in capsule endoscopy using a convolutional 6: OP03: Anti-SARS-CoV2 antibody responses are neural network M. Saraiva, Porto, Portugal 13:20 - 13:30 attenuated in patients with Inflammatory Bowel Disease treated with infliximab 18: How to set-up a virtual clinic? N. Kennedy, Exeter, United Kingdom 16:20 - 16:35 M. Pierik, Maastricht, The Netherlands 7: Combining biologics: Pros and cons 16:35- 16:45 Break 13:30 - 13:45 D. Rubin, Chicago, United States 16:45 - 17:45 Digital Oral Presentations (Sessions 1-5) 13:45 - 14:00 Break 17:45- 17:55 Break Scientific Session 2: Safety first? 14:00 - 15:15 M. Adamina, Winterthur, Switzerland 17:55 - 18:55 Industry Sponsored Satellite Symposia L. Lopetuso, Rome, Italy 2a , 2b & 2c 8: When do we really know the safety profile of a 14:00 - 14:15 drug? J. Rahier, Yvoir, Belgium 9: OP04: Safety analysis of filgotinib for Ulcerative Colitis: Results from the phase 2b/3 SELECTION study 14:15 - 14:25 and phase 3 SELECTIONLTE long-term extension study S. Schreiber, Kiel, Germany 4 16th Congress of ECCO - European Crohn‘s and Colitis Organisation July 2-3 & 8-10, 2021 • Virtual 5 Scientific programme day by day “IBD precise”
Friday, July 9, 2021 10:15 - 10:30 27: The future of radiology for IBD Scientific programme day by day A. Laghi, Rome, Italy 10:30 - 10:45 Break Industry Sponsored Morning Satellite Symposia Scientific Session 5: The young and the old 07:15 - 08:15 3a, 3b & 3c 10:45 - 12:00 T. Raine, Cambridge, United Kingdom P. Van Rheenen, Groningen, The Netherlands Scientific Session 4.1.: Next generation diagnostics 08:30 - 09:20 T. Kucharzik, Lüneburg, Germany 28: Lessons from paediatric IBD – early disease N. Yassin, Birmingham, United Kingdom 10:45 - 11:00 intervention, nutrition, genetic testing J. Van Limbergen, Amsterdam, The Netherlands 19: What histology can tell us: Are we speaking the same language? 29: OP15: Cyclic exclusive enteral nutrition to 08:30 - 08:50 R. Feakins, London, United Kingdom maintain longterm drug-free remission in Paediatric F. Magro Dias, Porto, Portugal 11:00 - 11:10 Crohn’s Disease: the CD HOPE study of the GETAID pédiatrique 20: OP09: Patient reported outcomes reflect B. Pigneur Arnaud, Paris, France 08:50 - 09:00 histologic disease activity in patients with Ulcerative Colitis: Interim analysis of the APOLLO study 11:10 - 11:25 30: Drug safety in the elderly patients with IBD B. Verstockt, Leuven, Belgium T. Lobatón Ortega, Ghent, Belgium 21: OP10: Response to biologics in IBD patients 31: OP16: Characterization of the Clinical Features assessed by Computerized image analysis of and Outcomes of Paediatric Patients with Isolated 09:00 - 09:10 Probe Based Confocal Laser Endomicroscopy with 11:25 - 11:35 Colonic Crohn’s Disease: A Multi-center Study from molecular labeling and gene expression profiling the Porto Group of ESPGHAN M. Iacucci, Birmingham, United Kingdom D. Shouval, Petah Tiqwa, Israel 22: OP11: Longitudinal profiling of mucosal 32: OP17: Impact of phenotypic and genetic factors immune cell composition using multiplex 11:35 - 11:45 on Crohn’s Disease evolution in a cohort of 13,926 09:10 - 09:20 immunohistochemistry identifies drug- and patients response-specific patterns in Ulcerative Colitis Q. Zhang, Cambridge, United Kingdom V. Volk, Hannover, Germany 11:45 - 12:00 33: Body image and sexuality 09:20 - 09:30 Break P. Tozer, London, United Kingdom Scientific Session 4.2.: Next generation diagnostics 12:00 - 12:10 Break 09:30 - 10:30 T. Kucharzik, Lüneburg, Germany Industry Sponsored Lunch Satellite Symposia LS1, N. Yassin, Birmingham, United Kingdom 12:10 - 12:50 LS2, LS3 & LS4 09:30 - 09:45 23: Fluorescence in IBD surgery 12:50 - 13:00 Break M. Slooter, Amsterdam, The Netherlands Scientific Session 6: Bottoms behaving badly 24: OP12: Blood proteins related to 13:00 - 14:15 A. Armuzzi, Rome, Italy immunoregulation or cellular junctions reveal Z. Zelinkova, Bratislava, Slovakia distinct biological profiles associated with the risk of 09:45 - 09:55 34: New surgical approaches for perianal disease short-term versus mid/long-term relapse in Crohn’s 13:00 - 13:15 P. Kotze, Curitiba, Brazil Disease patients stopping infliximab N. Pierre, Liège, Belgium 35: OP18: Treatment of perianal fistulas in Crohn’s Disease: Surgical closure after anti-TNF induction 25: OP13: Mucosal organoids capture Innate 13:15 - 13:25 treatment versus anti-TNF without surgery (PISA II) - Lymphoid Cells (ILC) tissue-specific development and A patient preference RCT 09:55 - 10:05 reveal that Inflammatory Bowel Disease-associated E. Meima-van Praag, Amsterdam, The Netherlands ILC modulate intestinal remodelling J. Neves, London, United Kingdom 36: Looking beyond anti-TNF 13:25 - 13:40 S. Vavricka, Zurich, Switzerland 26: OP14: Extracellular RNAs as liquid biopsy non- 37: OP19: Disease course and treatment outcomes 10:05 - 10:15 invasive biomarker in IBD of early resected Crohn‘s Disease patients: A Danish B. Verstockt, Leuven, Belgium 13:40 - 13:50 nationwide cohort study from 1997 to 2015 M. Zhao, Hvidovre, Denmark
6 16th Congress of ECCO - European Crohn‘s and Colitis Organisation July 2-3 & 8-10, 2021 • Virtual 7 Scientific programme day by day “IBD precise”
47: OP26: Risankizumab induces early clinical Friday, July 9, 2021, cont. remission and response in patients with Moderate- Scientific programme day by day 16:05 - 16:15 to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studies 38: OP20: Risk and predictors of surgery in a newly S. Schreiber, Kiel, Germany diagnosed cohort of IBD patients in the biologic era: 48: OP27- WITHDRAWN 13:50 - 14:00 Results from the EpidemIBD study M. Chaparro, Madrid, Spain 49: OP28: The effect of guselkumab induction 39: When it is not IBD therapy on early clinical outcome measures in 14:00 - 14:15 G. Bouguen, Rennes, France 16:15 - 16:25 patients with Moderately to Severely Active Crohn’s Disease: Results from the phase 2 GALAXI 1 study 14:15 - 14:30 Break S. Danese, Rozzano, Italy Scientific Session 7: Milestones in clinical care 16:25- 16:45 Break 14:30 - 15:20 R. Atreya, Erlangen, Germany P. Gionchetti, Bologna, Italy 16:45 - 17:45 Digital Oral Presentations (Sessions 6-10) 40: Endoscopy or ultrasound for disease activity 17:45- 17:55 Break assessment? 17:55 - 18:55 Industry Sponsored Satellite Symposia 4a, 4b & 4c 14:30 - 14:45 M. Iacucci, Birmingham, United Kingdom M. Allocca, Rozzano, Italy 41: OP21: Predictive value of Milan Ultrasound Crite- ria in Ulcerative Colitis: A prospective observational 14:45 - 14:55 cohort study M. Allocca, Rozzano, Italy 42: OP22: Factors independently associated with fatigue in IBD: Results from the baseline dataset of 14:55 - 15:05 the PREdiCCt study L. Derikx, Edinburgh, United Kingdom 43: ECCO Guidelines: Prevention and management of Opportunistic Infections 15:05 - 15:20 T. Kucharzik, Lüneburg, Germany S. Vavricka, Zurich, Switzerland 15:20 - 15:35 Break Scientific Session 8: IBD Horizons 15:35 - 16:25 B. Verstockt, Leuven, Belgium J. Torres, Loures, Portugal 44: OP23: Efficacy and safety of upadacitinib as induction therapy in patients with Moderately to 15:35 - 15:45 Severely Active Ulcerative Colitis: Results from phase 3 U-ACCOMPLISH study S. Vermeire, Leuven, Belgium 45: OP24: Efficacy and safety of upadacitinib induction therapy in patients with Moderately to 15:45 - 15:55 Severely Active Ulcerative Colitis: Results from the phase 3 U-ACHIEVE study S. Danese, Rozzano, Italy 46: OP25: Efficacy of filgotinib in patients with Ulcerative Colitis by line of therapy in the phase 15:55 - 16:05 2b/3 SELECTION trial I. Dotan, Petah Tikva, Israel
8 16th Congress of ECCO - European Crohn‘s and Colitis Organisation July 2-3 & 8-10, 2021 • Virtual 9 Scientific programme day by day “IBD precise”
Saturday, July 10, 2021 10:35 - 10:50 59: Deep healing Scientific programme day by day M. Ferrante, Leuven, Belgium 60: OP34: AJM300, an Oral Antagonist of α4- 07:15 - 08:15 Industry Sponsored Satellite Symposia 5a & 5b Integrin, as induction therapy for patients with moderately active Ulcerative Colitis: A Phase 3, Scientific Session 9: Basic Science: The microbiome 10:50 - 11:00 randomized, double-blind, placebo-controlled 08:30 - 09:55 as game changer in IBD? induction study A. Kaser, Cambridge, United Kingdom M. Watanabe, Tokyo, Japan P. Rosenstiel, Kiel, Germany 11:00 - 11:10 Break 50: Current knowledge: What is the problem with 08:30 - 08:45 FMT therapy? Scientific Session 10.2.: CD and UC: Similar disease M. Joossens, Ghent, Belgium burden and treatment goals? 11:10 - 12:00 Is it the organ or the disease process? 51: OP29: Long-term dietary patterns are associated I. Dotan, Petah Tikva, Israel with pro-inflammatory and anti-inflammatory A. Spinelli, Rozzano, Italy 08:45 - 08:55 features of the gut microbiome L. Bolte, Groningen, The Netherlands 61: Can we cure IBD with surgery? 11:10 - 11:30 J. Colombel, New York, United States 52: OP30: Lyophilised orally administered faecal T. Pinkney, Birmingham, United Kingdom microbiota transplantation for Active Ulcerative 08:55 - 09:05 Colitis (LOTUS study) 62: OP35: Effect of maintenance ustekinumab C. Haifer, Sydney, Australia on corticosteroid-free endoscopic and clinical 11:30 - 11:40 outcomes in patients with Crohn‘s Disease - Week 09:05 - 09:20 53: Precision editing of the gut microbiota 48 analysis of the STARDUST trial S. Zeissig, Dresden, Germany S. Danese, Rozzano, Italy 54: OP31: RESTORE: Interim analysis of a Phase 63: OP36: Risankizumab therapy induces 2 study of QBECO SSI for the induction and improvements in endoscopic endpoints in patients 09:20 - 09:30 maintenance of clinical and endoscopic remission in 11:40 - 11:50 with Moderate-to-Severe Crohn’s Disease: Results subjects with Moderate to Severe Crohn’s Disease from the phase 3 ADVANCE and MOTIVATE studies B. Bressler, Vancouver, Canada P. Bossuyt, Bonheiden, Belgium 55: OP32: Stool microbiome communities predict 64: OP37: Rapidity of symptom improvements remission in treatment-naïve Pediatric Crohn’s 09:30 - 09:40 during filgotinib induction therapy in patients with Disease patients 11:50 - 12:00 Ulcerative Colitis: Post hoc analysis of the phase C. Verburgt, Amsterdam, The Netherlands 2b/3 SELECTION study 56: Remote control of immune and metabolic S. Danese, Rozzano, Italy homeostasis by the gut microbiome and its 12:00 - 13:00 Break 09:40 - 09:55 potential impact on health M. Chamaillard, Lille, France 12:10 - 12:50 Industry Sponsored Satellite Symposia LS5 & LS6 09:55 - 10:10 Break Scientific Session 11: Personalised medicine 13:00 - 14:15 U. Kopylov, Tel Aviv, Israel Scientific Session 10.1.: CD and UC: Similar disease J. Gisbert, Madrid, Spain burden and treatment goals? 10:10 - 11:00 Is it the organ or the disease process? 13:00 - 13:15 65: Stratified management for mild and severe IBD? I. Dotan, Petah Tikva, Israel J. Halfvarson, Örebro, Sweden A. Spinelli, Rozzano, Italy 66: OP38: Developing a Cost-Effective Genomic 57: Disease burden Biomarker of Cancer Risk in Patients with Ulcerative 10:10 - 10:25 C. Le Berre, Nantes, France Colitis using Low-Pass Whole Genome Sequencing 13:15 - 13:25 of Unselected Endoscopic Biopsies: A Case-Control 58: OP33: Oral ritlecitinib and brepocitinib in Study patients with Moderate to Severe Active Ulcerative I. Al Bakir, London, United Kingdom 10:25 - 10:35 Colitis: Data from the VIBRATO umbrella study W. Sandborn, La Jolla, United States
10 16th Congress of ECCO - European Crohn‘s and Colitis Organisation July 2-3 & 8-10, 2021 • Virtual 11 Scientific programme day by day
Saturday, July 10, 2021, cont. Scientific programme day by day
67: Precision medicine to prevent disease 13:25 - 13:40 complications ECCO’21 M. Scharl, Zurich, Switzerland 68: OP39: The effect of phenotype and genotype on the plasma proteome in patients with Inflammatory New: All 13:40 - 13:50 Bowel Disease Webcasts A. Bourgonje, Groningen, The Netherlands sessions 69: OP40: Analysis of clinical features associated online! with favourable outcomes from ustekinumab treat- 13:50 - 14:00 to-target strategy in Crohn’s Disease patients in the STARDUST trial S. Danese, Rozzano, Italy 70: Personalised surgery in IBD 14:00 - 14:15 C. Buskens, Amsterdam, The Netherlands 14:15 - 14:25 Break Scientific Session 12: ECCO Lecture 14:25 - 15:15 L. Peyrin-Biroulet, Vandœuvre-Lès-Nancy, France B. Siegmund, Berlin, Germany 71: SARS-CoV-2 vaccination completed – end of 14:25 - 14:40 pandemic? T. Ahmad, Exeter, United Kingdom 72: ECCO Lecture: IBD clinical trials: Where do we 14:40 - 15:00 go from here? W. Sandborn, La Jolla, United States 15:00 - 15:15 The ECCO Film Missed an excellent presentation at the Congress? • All ECCO Members: Watch video recordings of ECCO’21 and past Congresses on the e-CCO Learning Platform • All registered ECCO’21 congress participants: Watch on-demand recordings on the virtual platform until the end of October • Availability is subject to speaker authorisation • Scientific programme webcasts • Digital oral presentation webcasts • Educational programme webcasts Scan and visit www.e-learning.ecco-ibd.eu 12 16th Congress of ECCO - European Crohn‘s and Colitis Organisation Digital oral presentations Digital oral presentations Digital oral presentations (DOP)
Thursday, July 8, 2021 Friday, July 9, 2021
16:45 - 17:45 Digital Oral Presentations Sessions 1-5 16:45 - 17:45 Digital Oral Presentations Sessions 6-10
Real-world evidence and pregnancy Digital Oral Presentation Molecular profiling Digital Oral Presentation A. Hart, London, United Kingdom Session 6 M. Iacucci, Birmingham, United Kingdom Session 1 Y. Chowers, Haifa, Israel A. Walsh, Manchester, United Kingdom Revisiting imaging and endoscopy Simple tools to predict drug response Digital Oral Presentation S. Vavricka, Zurich, Switzerland Digital Oral Presentation and disease course Session 2 G. Mantzaris , Athens, Greece Session 7 P. Juillerat, Bern, Switzerland New biomarkers S. Ghosh, Cork, Ireland Digital Oral Presentation S. Ben-Horin, Tel Aviv, Israel Evolving therapeutic strategies Session 3 R. Atreya, Erlangen, Germany Digital Oral Presentation E. Louis, Liege, Belgium Optimizing surgery outcomes Session 8 M. Löwenberg, Amsterdam, The Digital Oral Presentation M. Adamina, Winterthur, Switzerland Netherlands Session 4 W. Bemelman, Amsterdam, The Pharmacokinetics, COVID and new Netherlands Digital Oral Presentation classifications Recent advances in epidemiology Session 9 X. Roblin, Saint Etienne, France Digital Oral Presentation M. Aloi, Rome, Italy F. Magro Dias, Porto, Portugal Session 5 V. Pittet, Lausanne, Switzerland New data from landmark studies Digital Oral Presentation I. Dotan, Petah Tikva, Israel Session 10 A. Dignass, Frankfurt, Germany
14 16th Congress of ECCO - European Crohn‘s and Colitis Organisation July 2-3 & 8-10, 2021 • Virtual 15 e-Poster exhibition e-Poster Exhibition The e-Poster Exhibition is available online on the Virtual Congress Platform from June 28, 2021 until October 31, 2021. Why submit your
You can access the e-Poster Exhibition by clicking on ‘e-Posters’ on the Landing Page on the Virtual Congress Platform. research to JCC? You can filter all e-Posters by Abstract category and search for specific keywords. Feel free to get in touch with the authors via the contact form provided.
Prompt and professional peer review JCC publishes research that has undergone rigorous peer review, including an initial screening by one of the Editors and recommendations by independent reviewers. The average time from submission to first decision is two weeks.
High Impact Factor With its 2019 Impact Factor, which now stands at 8.658, JCC ranks highly among gastroenterology and hepatology journals. Scan and visit www.ecco-ibd.eu 16 16th Congress of ECCO - European Crohn‘s and Colitis Organisation July 2-3 & 8-10, 2021 • Virtual 17 3rd ECCO Basic Imaging Workshop 3rd ECCO Basic Imaging Workshop in collaboration with ESGAR in collaboration with ESGAR
Ultrasound and MRI – Hands-on bowel 08:05 - 10:35 ultrasonography and interactive discussion on Educational programme Ultrasound MRI workstations Management of suspected IBD ECCO aims to promote education and improve the quality of T. Kucharzik, Lüneburg, Germany care for IBD patients throughout Europe. Thus, ECCO offers J. Rimola, Barcelona, Spain the following educational activities on July 2 & 3, prior to the S. Vavricka, Zurich, Switzerland 16th Congress of ECCO, which is held virtually. N. Capozzi, Bologna, Italy Assessment of Crohn's Disease activity rd R. Wilkens, Copenhagen, Denmark 3 ECCO Basic Imaging J. Bjerrum, Copenhagen, Denmark C. Puylaert, Amsterdam, The Netherlands Workshop in collaboration with D. Bellini, Latina, Italy Intestinal complications of Crohn's Disease ESGAR C. Palmela, Loures, Portugal A. Gupta, London, United Kingdom Date: Friday, July 2, 2021 F. Petersen, Lüneburg, Germany Time: 07:30-15:20 J. Tielbeek, Amsterdam, The Netherlands Organisation: EduCom in collaboration with ESGAR 08:05 - 10:35 Recommended for: Physicians, Radiologists, Surgeons, Paediatricians Post-operative recurrence of Crohn's Disease Other professions are kindly invited to register. M. Allocca, Rozzano, Italy L. White, Sunshine Coast, Australia Registration: ECCO Membership 2021 required K. Horsthuis, Amsterdam, The Netherlands Online registration C. Bonifacio, Milan, Italy Registration fee: 120 EUR (incl. 20% Austrian VAT) 50% reduction for Y-ECCO, Affiliate & IBD Nurse Perianal Crohn's Disease Members D. Carter, Ramat Gan, Israel CME accreditation: 6 CME credits; prerequisite: completion of the F. Maccioni, Rome, Italy C. Maaser, Lüneburg, Germany online evaulation form M. Amitai, Tel Aviv, Israel Ulcerative Colitis K. Gecse, Amsterdam, The Netherlands Friday, July 2, 2021 A. Radmard, Tehran, Iran ECCO-ESGAR Basic Imaging Workshop IUS/MRI Part S. Cakovic-Cavka, Zagreb, Croatia P. Paolantonio, Rome, Italy 1: Welcome & Introduction 07:30 - 07:35 P. Paolantonio, Rome, Italy 10:35 - 11:05 Ultrasound and MRI – Lectures Part 2 C. Maaser, Lüneburg, Germany 4: When IUS, when MRI in daily IBD practice? 07:35 - 08:05 Ultrasound and MRI – Introductory lectures 10:35 - 11:05 T. Kucharzik, Lüneburg, Germany J. Rimola, Barcelona, Spain 07:35 - 07:50 2: Entero-MRI – What to look for 5: Farewell P. Paolantonio, Rome, Italy 11:05 - 11:10 P. Paolantonio, Rome, Italy 07:50 - 08:05 3: Intestinal ultrasound – What to look for C. Maaser, Lüneburg, Germany C. Palmela, Loures, Portugal 11:10 - 11:40 Break ECCO-ESGAR Basic Imaging Workshop Endoscopy Part 6: Welcome & Introduction 11:40 - 11:45 F. Magro Dias, Porto, Portugal M. Iacucci, Birmingham, United Kingdom Session 1: Endoscopy – Driving quality in IBD 11:45 - 13:05 endoscopy B. Hayee, London, United Kingdom
18 16th Congress of ECCO - European Crohn‘s and Colitis Organisation July 2-3 & 8-10, 2021 • Virtual 19 rd 3 ECCO Basic Imaging Workshop 19th IBD Intensive Course for Trainees in collaboration with ESGAR
7: Key quality indicators for endoscopy in IBD: Why th 11:45 - 12:00 do we need them? 19 IBD Intensive Course for M. Iacucci, Birmingham, United Kingdom 8: Interactive endoscopy video cases: How to score Trainees and how to write “good quality reports“ in UC and 12:00 - 12:15 CD? Date: Friday, July 2, 2021 R. Cannatelli, Brescia, Italy Time: 08:00-13:45 9: Interactive endoscopy video cases: How to Organisation: EduCom score and how to write a “good quality report “on Recommended for: Junior gastroenterologists 12:15 - 12:30 surveillance colonoscopy? Registration: ECCO Membership 2021 required. Upon M. Iacucci, Birmingham, United Kingdom invitation only 10: Interactive endoscopy video cases: How to CME accreditation: 5 CME credits; prerequisite: completion of the score and write a “good quality report “during online evaulation form 12:30 - 13:05 enteroscopy and pouchscopy? P. Ellul, Msida, Malta Friday, July 2, 2021 13:05 - 13:20 Break 1: Welcome & Introduction from the course director Session 2: Endoscopy – Surveillance and 08:00 - 08:05 H. Yanai, Petah Tikva, Israel management of dysplasia in IBD: Do we still need to F. Magro Dias, Porto, Portugal 13:20 - 14:20 use a dye in 2021? L. Peyrin-Biroulet, Vandœuvre-Lès-Nancy, France M. Iacucci, Birmingham, United Kingdom Session 1: Introduction and case-based 11: Dyeless or still dye chromoendoscopy: How do 08:05 - 09:30 management on conventional IBD therapies I use curriculum to achieve competency and be an Lead discussant: J. Lindsay, London, United Kingdom 13:20 - 13:35 excellent IBD endoscopist? 2: IBD: Epidemiology, immunopathogenesis, and R. Bisschops, Leuven, Belgium 08:05 - 08:30 their relevance to therapeutics 12: Advanced dysplasia characterization and I. Dotan, Petah Tikva, Israel 13:35 - 13:50 therapeutic management: New tools and techniques 3: 5-ASA compounds B. Hayee, London, United Kingdom 08:30 - 08:45 S. Hanauer, Chicago, United States 13: Interactive endoscopy video cases in dysplasia: 4: Thiopurines 13:50 - 14:20 What to look for and how to do it? 08:45 - 09:00 P. Irving, London, United Kingdom B. Hayee, London, United Kingdom 5: Methotrexate Session 3: Endoscopy - What is the future at the 09:00 - 09:15 P. Juillerat, Bern, Switzerland 14:20 - 15:20 horizon in IBD endoscopy? 6: Steroids P. Ellul, Msida, Malta 09:15 - 09:30 H. Yanai, Petah Tikva, Israel 14: Artificial Intelligence in IBD: Do I see better than 09:30 - 09:45 Break 14:20 - 14:40 we do? R. Bisschops, Leuven, Belgium Session 2: Case-based management of conventional 15: Interactive endoscopic video cases: How to score 09:45 - 11:25 IBD therapies 14:40 - 15:15 IBD activity through the endoscope and the AI eyes Lead discussant: A. Dignass, Frankfurt, Germany M. Iacucci, Birmingham, United Kingdom 09:45 - 10:05 7: Anti-TNF agents and TDM 16: Closing remarks P. Michetti, Lausanne, Switzerland 15:15 - 15:20 M. Iacucci, Birmingham, United Kingdom 8: Anti-integrins 10:05 - 10:20 J. Lindsay, London, United Kingdom 9: Anti-IL 23 10:20 - 10:35 M. Ferrante, Leuven, Belgium 10: JAK inhibitors 10:35 - 10:50 S. Vermeire, Leuven, Belgium 11: Medication in the pipeline 10:50 - 11:05 L. Peyrin-Biroulet, Vandœuvre-Lès-Nancy, France 12: Positioning therapeutic strategies in IBD 11:05 - 11:25 S. Ben-Horin, Ramat Gan, Israel 11:25 - 11:55 Break 20 16th Congress of ECCO - European Crohn‘s and Colitis Organisation July 2-3 & 8-10, 2021 • Virtual 21 19th IBD Intensive Course for Trainees 4th School for Clinical Trialists
Session 3: Round tables – 7 Themes / clinical cases 11:55 - 13:40 discussion th 13a: Pregnancy 4 School for Clinical Trialists J. van der Woude, Rotterdam, The Netherlands I. Dotan, Petah Tikva, Israel Date: Friday, July 2, 2021 13b: Extraintestinal manifestations Time: 08:00-10:55 K. Karmiris, Heraklion, Greece Organisation: ClinCom P. Lakatos, Budapest, Hungary Recommended for: Clinical trial coordinators, IBD Nurses and Allied 13c: When and how to start biologics? health professionals A. Dignass, Frankfurt, Germany Other professions are kindly invited to register. G. Mantzaris, Athens, Greece Registration: ECCO Membership 2021 required 13d: Complications associated with anti-TNF therapy Online registration 11:55 - 13:40 S. Ben-Horin, Ramat Gan, Israel Registration fee: 40 EUR (incl. 20% Austrian VAT) Y. Chowers, Haifa, Israel CME accreditation: 2 CME credits; prerequisite: completion of the 13e: Therapeutic Drug Monitoring online evaulation form P. Juillerat, Bern, Switzerland S. Vavricka, Zurich, Switzerland 13f: Exit strategy Friday, July 2, 2021 M. Ferrante, Leuven, Belgium 1: Welcome & Introduction G. Fiorino, Rozzano, Italy 08:00 - 08:05 13g: Therapeutic Endoscopy in IBD L. Beaugerie, Paris, France P. Michetti, Lausanne, Switzerland 08:05 - 09:25 Session 1: Drug efficacy H. Yanai, Petah Tikva, Israel P. Bossuyt, Bonheiden, Belgium 13:40 - 13:45 14: Summary and conclusions 2: Drug efficacy: What are the expectations? H. Yanai, Petah Tikva, Israel A. Walsh, Oxford, United Kingdom 08:05 - 08:25 G. Wakefield, Bicester, United Kingdom (Patient Representative) 3: Do we still need RCTs? 08:25 - 08:45 G. D‘Haens, Amsterdam, The Netherlands U. Kopylov, Tel Aviv, Israel 4: Personalized prediction: Statistician or algorithm? 08:45 - 09:05 S. Bonovas, Milan, Italy P. Dulai, San Diego, United States 5: Discussion A. Walsh, Oxford, United Kingdom G. Wakefield, Bicester, United Kingdom (Patient Representative) 09:05- 09:25 G. D’Haens, Amsterdam, The Netherlands U. Kopylov, Tel Aviv, Israel S. Bonovas, Milan, Italy P. Dulai, San Diego, United States P. Bossuyt, Bonheiden, Belgium 09:25 - 09:40 Break Session 2: Drug safety 09:40 - 10:50 L. Beaugerie, Paris, France 6: Classical pharmacovigilance: Still useful? (ANSM) 09:40 - 09:55 A. Inoubli, Saint-Denis, France
22 16th Congress of ECCO - European Crohn‘s and Colitis Organisation July 2-3 & 8-10, 2021 • Virtual 23 4th School for Clinical Trialists 12th N-ECCO School
th 7: How investigator-initiated studies have 12 N-ECCO School 09:55 - 10:10 substantially changed the safety profile of IBD drugs J. Kirchgesner, Paris, France Date: Friday, July 2, 2021 8: Communicating risks – IBD research nurse and Time: 09:30-14:15 physician perspective Organisation: N-ECCO 10:10 - 10:30 P. Bossuyt, Bonheiden, Belgium Recommended for: IBD Nurses, Dietitians K. Asnong, Bonheiden, Belgium Registration: ECCO Membership 2021 required. Upon 9: Discussion invitation only A. Inoubli, Saint-Denis, France (ANSM) CME accreditation: N/A J. Kirchgesner, Paris, France 10:30 - 10:50 P. Bossuyt, Bonheiden, Belgium Friday, July 2, 2021 K. Asnong, Bonheiden, Belgium 1: Welcome & Introduction L. Beaugerie, Paris, France 09:30 - 09:35 M. Ganon, Jerusalem, Israel 10: Closing remarks Session 1: Diagnosis and assessment 10:50 - 10:55 S. Sebastian, Hull, United Kingdom 09:35 - 11:55 M. Ganon, Jerusalem, Israel M. Campmans-Kuijpers, Groningen, The Netherlands 2: Diagnosis, anatomy and physiology in IBD 09:35 - 10:00 M. Ferrante, Leuven, Belgium 3: Psychosocial implications of living with IBD 10:00 - 10:20 W. Czuber-Dochan, London, United Kingdom 4: Nutritional assessment in IBD 10:20 - 10:40 L. Godny, Petah Tikva, Israel 10:40 - 10:55 Break 5: Surgery in IBD 10:55 - 11:15 M. Adamina, Winterthur, Switzerland 6: Medical treatment 11:15 - 11:35 J. Burisch, Hvidovre, Denmark 7: Adherence 11:35 - 11:55 S. Jäghult, Stockholm, Sweden 11:55 - 12:25 Break Session 2: Case studies – Disease management 12:25 - 13:15 P. Hartmann, Minden, Germany A. Ibarra, London, United Kingdom 8: UC Management 12:25 - 12:50 M. Samaan, London, United Kingdom 9: CD Management 12:50 - 13:15 N. Arebi, London, United Kingdom 13:15 - 13:30 Break Session 3: Multidisciplinary management in IBD 13:30 - 14:15 P. Hartmann, Minden, Germany W. Czuber-Dochan, London, United Kingdom 10: Nutritional management in IBD 13:30 - 13:50 C. Wall, Christchurch, New Zealand 11: Nursing roles in IBD management 13:50 - 14:10 A. Ibarra, London, United Kingdom 12: Closing remarks 14:10 - 14:15 M. Ganon, Jerusalem, Israel
24 16th Congress of ECCO - European Crohn‘s and Colitis Organisation July 2-3 & 8-10, 2021 • Virtual 25 8th ECCO Ultrasound Workshop – Advanced in collaboration with ESGAR
8th ECCO Ultrasound Workshop – Advanced in collaboration Free e-Learning with ESGAR Date: Friday, July 2, 2021 subscription Time: 13:00-16:35 Organisation: EduCom in collaboration with ESGAR Recommended for: Physicians, Radiologists, Surgeons, Paediatricians Other professions are kindly invited to register. Registration: ECCO Membership 2021 required Online registration Registration fee: 80 EUR (incl. 20% Austrian VAT) 50% reduction for Y-ECCO, Affiliate & IBD Nurse Members CME accreditation: 3 CME credits; prerequisite: completion of the online evaulation form Friday, July 2, 2021 1: Welcome & Introduction 13:00 - 13:05 C. Maaser, Lüneburg, Germany J. Rimola, Barcelona, Spain Session 1: Assessment of IBD 13:05 - 14:35 K. Gecse, Amsterdam, The Netherlands J. Rimola, Barcelona, Spain 2: IUS 2021 – What´s new for IUS in CD? 13:05 - 13:15 C. Maaser, Lüneburg, Germany 3: Interactive video presentation 1 - IUS in CD - Your 13:15 - 13:35 diagnosis? C. Maaser, Lüneburg, Germany Open to all Healthcare Professionals 4: IUS 2021 – What´s new for IUS in UC? not older than 35 or still in training 13:35 - 13:45 C. Palmela, Loures, Portugal 5: Interactive video presentation 2 - IUS in UC - Your 13:45 - 14:05 diagnosis? • Improve your knowledge and enhance your educational C. Palmela, Loures, Portugal experience with e-CCO Learning 6: Postoperative monitoring – Tips and Tricks • Take advantage of advanced learning opportunities in 14:05 - 14:15 M. Alloca, Rozzano, Italy IBD with one click 7: Interactive video presentation 3 - Postoperative • Browse the ECCO e-Library for material as of ECCO’16 14:15 - 14:35 IUS - Your diagnosis onwards M. Alloca, Rozzano, Italy • No ECCO Membership required: An ECCO Account is all 14:35 - 14:50 Break you need • Log-in via the new ECCO Portal for automatic access • Renewal of the access every year (if eligible)
Scan and visit www.e-learning.ecco-ibd.eu July 2-3 & 8-10, 2021 • Virtual 27 8th ECCO Ultrasound Workshop – 5th Advanced ECCO: Advanced in collaboration with ESGAR EduCational COurse for Industry
Session 2: IUS special situations th 14:50 - 16:35 M. Allocca, Rozzano, Italy 5 Advanced ECCO: J. Rimola, Barcelona, Spain 8: Is it IBD? EduCational COurse for 14:50 - 15:00 F. Petersen, Lüneburg, Germany 9: Interactive video presentation 4 - What’s your Industry 15:00 - 15:20 diagnosis? F. Petersen, Lüneburg, Germany Date: Friday, July 2, 2021 10: Contrast enhanced ultrasound and elastography Time: 14:30-17:05 15:20 - 15:30 for IBD monitoring? Organisation: ClinCom K. Gecse, Amsterdam, The Netherlands Recommended for: Corporate Members & Non-Corporate Members 11: Interactive video presentation 5 Registration: ECCO Membership 2021 NOT required 15:30 - 15:50 F. de Voogd, Amsterdam, The Netherlands Registration fee: 12: Perineal ultrasound Non-Corporate Members: 600 EUR (incl. 20% 15:50 - 16:00 D. Carter, Ramat Gan, Israel Austrian VAT) ECCO Corporate Members: 400 EUR (incl. 20% 13: Interactive video presentation 6 Austrian VAT) 16:00 - 16:20 D. Carter, Ramat Gan, Israel CME accreditation: N/A 14: Post course test, summary and closing remarks 16:20 - 16:35 C. Maaser, Lüneburg, Germany Friday, July 2, 2021 1: Welcome & Introduction 14:30 - 14:35 L. Peyrin-Biroulet, Vandœuvre-Lès-Nancy, France Session 1: Precision medicine in IBD therapy 14:35 - 15:40 S. Sebastian, Hull, United Kingdom 2: Precision choice in therapy 14:35 - 14:50 S. Vermeire, Leuven, Belgium 3: Precision risk stratification 14:50 - 15:05 E. Louis, Liège, Belgium 4: Precision monitoring 15:05 - 15:20 G. Rogler, Zurich, Switzerland 5: Discussion E. Louis, Liège, Belgium G. Rogler, Zurich, Switzerland 15:20 - 15:40 S. Sebastian, Hull, United Kingdom S. Vermeire, Leuven, Belgium K. Park, San Francisco, United States (Roche Genentech) 15:40 - 15:55 Break Session 2: How to fill in the gaps of knowledge in 15:55 - 17:05 orphan IBD populations L. Beaugerie, Paris, France 6: Clinical trials: Lessons from the past 15:55 - 16:10 G. D‘Haens, Amsterdam, The Netherlands 7: Orphan fields in IBD 16:10 - 16:25 K. Gecse, Amsterdam, The Netherlands 8: Filling the Gaps 16:25 - 16:40 S. Danese, Rozzano, Italy
28 16th Congress of ECCO - European Crohn‘s and Colitis Organisation July 2-3 & 8-10, 2021 • Virtual 29 th 5 Advanced ECCO: th EduCational COurse for Industry 7 Y-ECCO Basic Science Workshop
9: Discussion th L. Beaugerie, Paris, France 7 Y-ECCO Basic Science G. D‘Haens, Amsterdam, The Netherlands K. Gecse, Amsterdam, The Netherlands Workshop 16:40 - 17:00 S. Danese, Rozzano, Italy S. Milicevic, Zurich, Switzerland (Takeda) Date: Friday, July 2, 2021 A. Rose, London, United Kingdom (Patient Time: 14:30-17:45 Representative) Organisation: Y-ECCO 17:00 - 17:05 10: Closing remarks Recommended for: Basic scientists, Physicians, Paediatricians, S. Sebastian, Hull, United Kingdom Surgeons, IBD Nurses Other professions are kindly invited to register. Registration: ECCO Membership 2021 required Online registration Registration fee: 65 EUR (incl. 20% Austrian VAT) 50% reduction for Y-ECCO, Affiliate & IBD Nurse Members CME accreditation: 2 CME credits; prerequisite: completion of the online evaulation form Friday, July 2, 2021 1: Introduction 14:30 - 14:35 C. Hedin, Stockholm, Sweden Session 1: Systems biology 14:35 - 15:40 C. Hedin, Stockholm, Sweden S. Schreiber, Kiel, Germany 2: Generating complex data to unravel IBD 14:35 - 14:55 S. Schreiber, Kiel, Germany 3: Abstract presentation: αEβ7 positive γδ T cells are associated with mucosal healing in Ulcerative Colitis 14:55 - 15:10 and have a homeostatic immunophenotype R. Dart, London, United Kingdom 4: Abstract presentation: Ulcerative Colitis associated single nucleotide polymorphisms found in transcription factor binding sites effect 15:10 - 15:25 key pathogenesis pathways and facilitate patient stratification D. Modos, Cambridge, United Kingdom 5: Abstract presentation: Serum proteomics predict endoscopic remission in patients with Crohn’s 15:25 - 15:40 Disease D. Alsoud, Leuven, Belgium 15:40 - 15:50 Break
30 16th Congress of ECCO - European Crohn‘s and Colitis Organisation July 2-3 & 8-10, 2021 • Virtual 31 7th Y-ECCO Basic Science Workshop 6th D-ECCO Workshop
Session 2: Modelling IBD th 15:50 - 16:55 M. Samaan, London, United Kingdom 6 D-ECCO Workshop S. Zeissig, Dresden, Germany 6: Models of IBD Date: Saturday, July 3, 2021 15:50 - 16:10 S. Zeissig, Dresden, Germany Time: 08:15-11:50 Organisation: D-ECCO 7: Abstract presentation: Endoscopically injected allogeneic mesenchymal stromal cells alter the Recommended for: Dietitians, IBD Nurses, Physicians 16:10 - 16:25 mucosal immune cell compartment in patients with Other professions are kindly invited to register. Ulcerative Proctitis Registration: ECCO Membership 2021 required L. Ouboter, Amsterdam, The Netherlands Online registration 8: Abstract presentation: Effects of exposure to Registration fee: 40 EUR (incl. 20% Austrian VAT) steroids on the PredictSURE whole blood prognostic CME accreditation: 3 CME credits; prerequisite: completion of the 16:25 - 16:40 assay in Inflammatory Bowel Disease online evaulation form D. Alsoud, Leuven, Belgium 9: Abstract presentation: Development of human Saturday, July 3, 2021 embryonic stem cell-derived intestinal organoids 1: Welcome 16:40 - 16:55 for in vitro studies on intestinal inflammation and 08:15 - 08:20 M. Campmans-Kuijpers, Groningen, The Netherlands fibrosis Session 1: Science, diet and IBD E. Filidou, Alexandroupolis, Greece 08:20 - 09:30 C. Wall, Christchurch, New Zealand 16:55 - 17:05 Break D. O‘Hanlon, London, United Kingdom Session 3: Basic Science Reserach Fellowships 08:20 - 08:38 2: Food additives and their effect on the microbiome 17:05 - 17:40 J. Burisch, Hvidovre, Denmark A. Levine, Holon, Israel G. Pellino, Aversa, Italy 08:38 - 08:56 3: Personalized nutrition in IBD – Are we there yet? 10: From bench to research group leader L. Godny, Petah Tikva, Israel 17:05 - 17:25 R. Atreya, Erlangen, Germany 08:56 - 09:15 4: Fermented foods – fad or fix? 11: ECCO Fellowship presentation: Targeting CD4+ M. Campmans-Kuijpers, Groningen, The Netherlands 17:25 - 17:40 T-cell plasticity in IBD 5: The future of using nutrition to alter the A. Machicote, Hamburg, Germany 09:15 - 09:30 microbiome 12: Closing remarks and Y-ECCO best abstract E. Wine, Edmonton, Canada 17:40 - 17:45 awards 09:30 - 09:45 Break J. Burisch, Hvidovre, Denmark Session 2: Practical clinical nutrition in IBD 09:45 - 10:30 M. Campmans-Kuijpers, Groningen, The Netherlands L. Godny, Petah Tikva, Israel 6: Nutritional assessment 09:45 - 10:00 E. Halmos, Melbourne, Australia 7: Eating for Two: Nutrition and Pregnancy 10:00 - 10:15 C. Wall, Christchurch, New Zealand 8: OMG it’s OFG: Dietary management of Orofacial 10:15 - 10:30 granulomatous D. O‘Hanlon, London, United Kingdom 10:30 - 10:45 Break
32 16th Congress of ECCO - European Crohn‘s and Colitis Organisation July 2-3 & 8-10, 2021 • Virtual 33 6th D-ECCO Workshop 1st ECCO Postgraduate Course in IBD
Session 3: Panel discussion / Interactive session st 10:45 - 11:50 C. Wall, Christchurch, New Zealand 1 ECCO Postgraduate Course D. O‘Hanlon, London, United Kingdom 9: Abstract presentation 1: Food-related quality of in IBD life in adults with Inflammatory Bowel Disease is influenced by restrictive eating behaviour, disease Date: Saturday, July 3, 2021 10:45 - 10:55 activity and surgery: A prospective multi-centre Time: 08:30-12:25 study Organisation: EduCom A. Day, Adelaide, Australia Recommended for: Experienced Gastroenterologists with interest in 10: Abstract presentation 2: Risk of eating IBD disorders in Italian children and adolescents with Other professions are kindly invited to register. 10:55 - 11:05 Inflammatory Bowel Disease: results of a multicenter Registration: ECCO Membership 2021 required nationwide study Online registration S. Gatti, Ancona, Italy Registration fee: 65 EUR (incl. 20% Austrian VAT) 11: Will emerging diets replace medical therapy in CME accreditation: 3 CME credits; prerequisite: completion of the IBD? online evaulation form 11:05- 11:25 E. Halmos, Melbourne, Australia M. Samaan, London, United Kingdom Saturday, July 3, 2021 12: Interactive Session E. Halmos, Melbourne, Australia 1: Introduction 11:25- 11:45 M. Samaan, London, United Kingdom 08:30 - 08:35 P. Juillerat, Bern, Switzerland C. Wall, Christchurch, New Zealand H. Yanai, Petah Tikva, Israel D. O‘Hanlon, London, United Kingdom F. Magro Dias, Porto, Portugal 13: Closing remarks Session 1: Prepare yourself with IBD Experts 11:45 - 11:50 M. Campmans-Kuijpers, Groningen, The Netherlands 08:35 - 10:05 P. Juillerat, Bern, Switzerland J. van der Woude, Rotterdam, The Netherlands 2: How important is IBD? 08:35 - 08:50 S. Vermeire, Leuven, Belgium 3: How to diagnose and evaluate a new IBD case? 08:50 - 09:05 L. Peyrin-Biroulet, Vandœuvre-Lès-Nancy, France 4: How to optimise the old school IBD Meds? 09:05 - 09:30 S. Ben-Horin, Ramat Gan, Israel 5: How to place new biologics and small molecules? 09:30 - 09:55 S. Danese, Rozzano, Italy 6: How to place surgery in IBD? 09:55 - 10:05 P. Kotze, Curitiba, Brazil 10:05 - 10:20 Break Session 2: Case-based discussion with IBD Experts 10:20 - 12:25 H. Yanai, Petah Tikva, Israel P. Juillerat, Bern, Switzerland 7: UC cases presentation 10:20 - 10:50 S. Restellini, Geneva, Switzerland 8: Discussion S. Restellini, Geneva, Switzerland 10:50 - 11:20 P. Juillerat, Bern, Switzerland G. Doherty, Dublin, Ireland G. Rogler, Zurich, Switzerland
34 16th Congress of ECCO - European Crohn‘s and Colitis Organisation July 2-3 & 8-10, 2021 • Virtual 35 th st 10 S-ECCO IBD Masterclass in 1 ECCO Postgraduate Course in IBD collaboration with ESCP
11:20 - 11:50 9: CD cases presentation th T. Lobatón, Leuven, Belgium 10 S-ECCO IBD Masterclass 10: Discussion T. Lobatón, Leuven, Belgium 11:50 - 12:20 H. Yanai, Petah Tikva, Israel in collaboration with ESCP B. Siegmund, Berlin, Germany Date: Saturday, July 3, 2021 J. Colombel, New York, United States Time: 08:30-16:00 11: Conclusion and remarks Organisation: S-ECCO in collaboration with ESCP 12:20 - 12:25 P. Juillerat, Bern, Switzerland Recommended for: Surgeons, Physicians, IBD Nurses H. Yanai, Petah Tikva, Israel Other professions are kindly invited F. Magro Dias, Porto, Portugal to register. Registration: ECCO Membership 2021 required Online registration Registration fee: 120 EUR (incl. 20% Austrian VAT) 50% reduction for Y-ECCO, Affiliate & IBD Nurse Members CME accreditation: 4 CME credits; prerequisite: completion of the online evaulation form Saturday, July 3, 2021 1: Welcome 08:30 - 08:35 M. Adamina, Winterthur, Switzerland Session 1: Hot questions in IBD surgery: The fistulizing session 08:35 - 09:55 O. Faiz, Harrow, United Kingdom Y. Panis, Clichy, France 08:35 - 09:15 Debate 1: What to do with these abdominal fistula? 2: Enterocutaneous fistula 08:35 - 08:50 P. Myrelid, Linköping, Sweden 3: Urinary fistula 08:50 - 09:05 G. Sampietro, Milan, Italy 4: Discussion 09:05 - 09:15 P. Myrelid, Linköping, Sweden G. Sampietro, Milan, Italy 09:15 - 09:55 Debate 2: Pelvic fistula is a nightmare! 5: Pouch fistula 09:15 - 09:30 W. Bemelman, Amsterdam, The Netherlands 6: Rectovaginal fistula 09:30 - 09:45 P. Fleshner, Los Angeles, United States 7: Discussion 09:45 - 09:55 W. Bemelman, Amsterdam, The Netherlands P. Fleshner, Los Angeles, United States 09:55 - 10:05 Break
36 16th Congress of ECCO - European Crohn‘s and Colitis Organisation July 2-3 & 8-10, 2021 • Virtual 37 10th S-ECCO IBD Masterclass in 10th S-ECCO IBD Masterclass in collaboration with ESCP collaboration with ESCP
Session 2: The scientific IBD surgeon: 13:20 - 13:30 Break 10:05 - 11:05 Trial updates 13:30 - 14:30 S-ECCO IBD Masterclass Satellite Symposium Slot C. Buskens, Amsterdam, The Netherlands 14:30 - 14:40 Break P. Myrelid, Linköping, Sweden Session 4: Expertise in IBD management: What does 10:05 - 10:20 9: Perioperative pathway of care in IBD patients it mean? M. Adamina, Winterthur, Switzerland 14:40 - 15:25 M. Adamina, Winterthur, Switzerland 10:20 - 10:35 10: Achieving high performance in IBD surgery P. Kotze, Curitiba, Brazil O. Faiz, Harrow, United Kingdom 25: How to train to become IBD surgeon? 10:35- 11:05 Trial updates 14:40 - 14:55 G. Pellino, Aversa, Italy 13: The VALIDate study: Giving a voice to the IBD 26: Transitioning paediatric patients to adults IBD 10:35 - 10:45 patient 14:55 - 15:10 care C. Le Berre, Nantes, France D. Wilson, Edinburgh, United Kingdom 14: The MIND study: Assessment of psychological 27: Perineal sinus after total coloproctectomy for 10:45 - 10:55 characteristics and postop outcomes 15:10 - 15:25 CD: How to prevent? How to treat? C. Foppa, Milan, Italy P. Kienle, Mannheim, Germany 15: The COSTA study : COlonic Salvage by Session 5: Consultants’ corner on challenging cases 10:55 - 11:05 Therapeutic Appendectomy M. Adamina, Winterthur, Switzerland C. Buskens, Amsterdam, The Netherlands 15:25 - 15:55 P. Kotze, Curitiba, Brazil 11:05 - 11:15 Break P. Fleshner, Los Angeles, United States W. Bemelman, Amsterdam, The Netherlands Session 3: Ten years after: The history of IBD surgery A. Hart, London, United Kingdom 11:15 - 13:20 W. Bemelman, Amsterdam, The Netherlands P. Kienle, Mannheim, Germany 28: First clinical case 15:25 - 15:40 M. Carvello, Rozzano, Italy 16: 10 years of surgery for intestinal Crohn’s Disease 11:15 - 11:30 A. D‘Hoore, Leuven, Belgium 29: Second clinical case 15:40 - 15:55 P. Tozer, London, United Kingdom 18: 10 years of surgery for Crohn’s perineal disease 11:30 - 11:45 P. Kotze, Curitiba, Brazil 30: Closing remarks 15:55 - 16:00 M. Adamina, Winterthur, Switzerland 17: 10 years of surgery for Ulcerative Colitis 11:45 - 12:00 Y. Panis, Clichy, France 19: Ten years after: The S-ECCO history 12:00 - 12:10 C. Buskens, Amsterdam, The Netherlands 12:10 - 12:40 Surgical technique session: How I do it ? 20: Adapting surgical strategy to preoperative 12:10 - 12:25 treatment A. Lightner, Cleveland, United States 21: TTSS for low anastomosis in IBD patients 12:25 - 12:40 A. Spinelli, Rozzano, Italy 12:40 - 13:20 Surgical technique session: The redo-session 22: Redo pouch 12:40 - 12:55 J. Warusavitarne, Harrow, United Kingdom 23: Redosurgery for intestinal Crohn’s Disease 12:55 - 13:10 O. Zmora, Tel Aviv, Israel 24: Discussion 13:10 - 13:20 J. Warusavitarne, Harrow, United Kingdom O. Zmora, Tel Aviv, Israel
38 16th Congress of ECCO - European Crohn‘s and Colitis Organisation July 2-3 & 8-10, 2021 • Virtual 39 6th H-ECCO IBD Masterclass 6th H-ECCO IBD Masterclass
11: Modification of IBD histology by medical and th 11:30 - 11:45 surgical therapy 6 H-ECCO IBD Masterclass M. Tripathi, Cambridge, United Kingdom 12: Datasets and standards for IBD pathology Date: Saturday, July 3, 2021 11:45 - 12:00 R. Feakins, London, United Kingdom Time: 09:00-15:55 13: Slide seminar Organisation: H-ECCO, endorsed by ESP 12:00 - 12:10 P. Baldin, Woluwe Saint Lambert, Belgium Recommended for: Histopathologists, Clinicians Other professions are kindly invited to register. 12:10- 12:40 Break Registration: ECCO Membership 2021 required Session 3: Neoplasia Online registration 12:40 - 14:10 J. Lindsay, London, United Kingdom M. Svrcek, Paris, France Registration fee: 65 EUR (incl. 20% Austrian VAT) 50% reduction for Y-ECCO, Affiliate & IBD Nurse 12:40 - 12:55 14: Tumours in IBD – Clinician Members J. Lindsay, London, United Kingdom CME accreditation: 5 CME credits; prerequisite: completion of the 15: Primary sclerosing cholangitis and online evaulation form 12:55 - 13:10 cholangiocarcinoma Saturday, July 3, 2021 F. Rosini, Bologna, Italy 13:10 - 13:25 16: Nonepithelial neoplasia in IBD 1: Welcome & Introduction P. Baldin, Woluwe Saint Lambert, Belgium 09:00 - 09:05 G. De Hertogh, Leuven, Belgium 13:25 - 13:40 17: Neuroendocrine proliferations in IBD Session 1: Basics of IBD S. Walsh, Dundee, United Kingdom 09:05 - 10:30 P. Bossuyt, Bonheiden, Belgium 18: Slide seminar A. Driessen, Edegem, Belgium 13:40 - 13:50 A. Driessen, Edegem, Belgium 09:05- 09:20 2: Patient’s view: What are the priorities? 19: Intestinal adenocarcinoma in IBD P. Hartmann, Minden, Germany 13:50 - 14:10 M. Svrcek, Paris, France 3: Surgeon’s view: When is pathology useful? 14:10 - 14:25 Break 09:20 - 09:35 M. Adamina, Winterthur, Switzerland Session 4: New concepts 09:35 - 09:50 4: Pathologist’s view: Macroscopic pathology of IBD 14:25 - 15:50 G. De Hertogh, Leuven, Belgium M. Tripathi, Cambridge, United Kingdom P. Baldin, Woluwe Saint Lambert, Belgium 09:50 - 10:05 5: Pathologist’s view: Biopsy features of IBD 20: Hot topics in IBD P. Baldin, Woluwe Saint Lambert, Belgium 14:25 - 14:40 G. De Hertogh, Leuven, Belgium 10:05 - 10:20 6: Gastroenterologist’s view: Features of IBD 21: Fibrosis in IBD and its assessment P. Irving, London, United Kingdom 14:40 - 14:55 R. Feakins, London, United Kingdom 10:20 - 10:30 7: Slide seminar – Macroscopic pathology of IBD 22: Digital pathology and artificial intelligence in F. Rosini, Bologna, Italy 14:55 - 15:10 IBD pathology 10:30 - 10:45 Break F. Rosini, Bologna, Italy Session 2: Scoring schemes and standards 15:10 - 15:25 23: Newer and rarer mimics of IBD histology 10:45- 12:10 F. Rosini, Bologna, Italy A. Driessen, Edegem, Belgium R. Feakins, London, United Kingdom 15:25 - 15:40 24: The pancreas and IBD 8: Sampling issues – Clinician and pathologist I. Esposito, Düsseldorf, Germany 10:45 - 11:00 F. Magro Dias, Porto, Portugal 25: Slide seminar A. Driessen, Edegem, Belgium 15:40 - 15:50 G. De Hertogh, Leuven, Belgium 9: Scoring schemes for IBD – Clinician and 26: Closing remarks pathologist 15:50 - 15:55 G. De Hertogh, Leuven, Belgium 11:00 - 11:15 F. Magro Dias, Porto, Portugal G. De Hertogh, Leuven, Belgium 10: Discussion about scoring systems F. Magro Dias, Porto, Portugal 11:15 - 11:30 A. Driessen, Edegem, Belgium G. De Hertogh, Leuven, Belgium
40 16th Congress of ECCO - European Crohn‘s and Colitis Organisation July 2-3 & 8-10, 2021 • Virtual 41 9th SciCom Workshop 15th N-ECCO Network Meeting
9th SciCom Workshop: 15th N-ECCO Network Meeting Precision medicine in IBD: Disease Date: Saturday, July 3, 2021 prevention, progression and therapy Time: 10:00-15:00 Organisation: N-ECCO outcomes Target audience: IBD Nurses - advanced level Date: Saturday, July 3, 2021 Registration: ECCO Membership 2021 required Online registration Time: 09:45-11:45 Registration fee: 20 EUR (incl. 20% Austrian VAT) Organisation: SciCom CME accreditation: N/A Recommended for: Basic scientists and interested clinicians Other professions are kindly invited to register. Registration: ECCO Membership 2021 required Online registration Saturday, July 3, 2021 Registration fee: 65 EUR (incl. 20% Austrian VAT) 10:00 - 10:05 1: Welcome & Introduction 50% reduction for Y-ECCO, Affiliate & IBD Nurse S. Jäghult, Stockholm, Sweden Members Session 1: Treatments in IBD CME accreditation: 1 CME credit; prerequisite: completion of the 10:05 - 11:05 P. Hartmann, Minden, Germany online evaulation form S. Jäghult, Stockholm, Sweden 2: What is new in IBD treatment? Saturday, July 3, 2021 10:05 - 10:20 B. Siegmund, Berlin, Germany Precision medicine in IBD - Part 1 3: Complimentary treatment 09:45 - 10:35 M. Ferrante, Leuven, Belgium 10:20 - 10:35 J. Langhorst, Bamberg, Germany S. Zeissig, Dresden, Germany 10:35 - 10:50 4: CBD and marihuana 09:45 - 09:50 1: Welcome & Introduction U. Kopylov, Tel Aviv, Israel S. Zeissig, Dresden, Germany 5: Faecal transplantation as treatment in IBD 2: Can you prevent disease 10:50 - 11:05 A. Hart, London, United Kingdom 09:50 - 10:12 J. Torres, Loures, Portugal 11:05 - 11:20 Break 3: Prediction of the disease course 10:12 - 10:35 J. Lee, Cambridge, United Kingdom Session 2: Innovation in Research and practice 11:20 - 12:20 W. Czuber-Dochan, London, United Kingdom 10:35 - 10:50 Break E. Kjaer-Mikkelsen, Herning, Denmark Precision medicine in IBD - Part 2 6: Polypharmacy in older patients 10:50 - 11:45 M. Scharl, Zurich, Switzerland 11:20 - 11:40 A. Hart, London, United Kingdom K. Papamichail, Boston, United States 7: Abstract Presentation 1: N01: Does physical 10:50 - 11:12 4: Predicting response to therapy activity positively impact fatigue in individuals with B. Verstockt, Leuven, Belgium 11:40 - 11:50 Inflammatory Bowel Disease? 5: Can you cure established disease D. Farrell, Cork, Ireland 11:12 - 11:40 Y. Panis, Clichy, France 8: Abstract Presentation 2: N02: PREVIEW study: C. Fiocchi, Cleveland, United States Factors associated with willingness to switch from 11:40 - 11:45 6: Closing remarks intravenous to subcutaneous formulations of CT- M. Scharl, Zurich, Switzerland 11:50 - 12:00 P13 and vedolizumab in patients with Inflammatory Bowel Disease. K. Asnong, Bonheiden, Belgium 9: Abstract Presentation 3: N03: Information flow experiences during COVID-19 in IBD patients: A 12:00 - 12:10 prospective observational study E. De Dycker, Rotselaar, Belgium
42 16th Congress of ECCO - European Crohn‘s and Colitis Organisation July 2-3 & 8-10, 2021 • Virtual 43 15th N-ECCO Network Meeting 8th P-ECCO Educational Course
10: Abstract Presentation 4: N04: Being an IBD th Clinical Nurse Specialist in the UK National 8 P-ECCO Educational Course 12:10 - 12:20 Health Service: Challenges, Stressors and Coping Mechanisms Date: Saturday, July 3, 2021 L. Dibley, London, United Kingdom Time: 13:05-14:25 12:20 - 12:25 Break Organisation: P-ECCO 12:25 - 13:25 N-ECCO Network Meeting Satellite Symposium Slot Recommended for: Paediatricians, Physicians, Surgeons 13:25 - 13:35 Break Other professions are kindly invited to register. Registration: ECCO Membership 2021 required Session 3: IBD Nurse role in management of IBD Online registration 13:35 - 14:10 A. Ibarra, London, United Kingdom A. Rivera, Barcelona, Spain Registration fee: 65 EUR (incl. 20% Austrian VAT) 50% reduction for Y-ECCO, Affiliate & IBD Nurse 11: Ongoing Symptoms in patients in remission – Members 13:35 - 13:50 How to deal with them? G. Rogler, Zurich, Switzerland CME accreditation: 1 CME credit; prerequisite: completion of the online evaulation form 12: Nurses role in surgical pathway - A Tandem talk 13:50 - 14:10 K. Kemp, Manchester, United Kingdom J. Odita, London, United Kingdom 14:10 - 14:25 Break Saturday, July 3, 2021 Session 4: MDT Session – Q&A Session 13:05 - 14:25 Food for thought in IBD 14:25 - 14:55 W. Czuber-Dochan, London, United Kingdom D. Wilson, Edinburgh, United Kingdom 13: Q&A Session 1: Welcome S. Jäghult, Stockholm, Sweden 13:05 - 13:10 D. Wilson, Edinburgh, United Kingdom E. Langholz, Herlev, Denmark 2: Contemporary nutritional approach in adult IBD 14:25 - 14:55 P. Myrelid, Linköping, Sweden 13:10 - 13:30 I. Dotan, Petah Tikva, Israel M. Campmans-Kuijpers, Groningen, The Netherlands L. Godny, Petah Tikva, Israel A. Duff, London, United Kingdom L. Inganäs, Stockholm, Sweden 3: Multidisciplinary approaches for nutritional thera- 14: Closing remarks 13:30 - 13:50 py at the poles of the life cycle - PIBD and elderly IBD 14:55- 15:00 S. Jäghult, Stockholm, Sweden D. O’Hanlon, London, United Kingdom E. Wine, Edmonton, Canada 4: Nutritional issues at transition in IBD 13:50 - 14:05 M. Aloi, Rome, Italy 5: Towards personalized dietary therapy 14:05 - 14:25 J. Van Limbergen, Amsterdam, The Netherlands
44 16th Congress of ECCO - European Crohn‘s and Colitis Organisation July 2-3 & 8-10, 2021 • Virtual 45 2nd Guideline Methodology 2nd Guideline Methodology and GRADE Workshop and GRADE Workshop
nd 9: How much can we streamline GRADE process 2 Guideline Methodology - United States vs ECCO perspectives / Do we need multiple sets of international (and national) 16:00 - 16:15 guidelines? and GRADE Workshop T. Raine, Cambridge, United Kingdom Date: Saturday, July 3, 2021 D. Rubin, Chicago, United States Time: 13:30-16:35 10: How does Cochrane collaboration sit alongside Organisation: GuiCom ECCO guidelines? 16:15 - 16:30 T. Raine, Cambridge, United Kingdom Target audience: All healthcare professionals who are interested in M. Gordon, Preston, United Kingdom guidelines and guideline development Registration: ECCO Membership 2021 required 16:30 - 16:35 11: Summary and conclusions Online registration T. Raine, Cambridge, United Kingdom Registration fee: 40 EUR (incl. 20% Austrian VAT) CME accreditation: 2 CME credits; prerequisite: completion of the online evaulation form Saturday, July 3, 2021 Session 1: Hot topic in IBD guidelines 13:30 - 15:00 A. Spinelli, Rozzano, Italy T. Kucharzik, Lüneburg, Germany 1: Welcome & Introduction: Integrating the GRADE methodology into the ECCO guidelines - how far 13:30 - 13:40 have we come and where are we going? T. Raine, Cambridge, United Kingdom 2: What is GRADE? An introduction to the 13:40 - 14:05 methodology with practical examples S. Bonovas, Milan, Italy 3: Putting GRADE into practice – some examples 14:05 - 14:30 of workflow T. Lytras, Athens, Greece 4: How do we measure quality in guidelines? 14:30 - 14:45 J. Torres, Loures, Portugal 5: An ACG perspective on challenges in an era of ever 14:45 - 15:00 increasing guideline rigor D. Rubin, Chicago, United States 15:00 - 15:15 Break Session 2: Controversies in guideline development 15:15 - 16:30 T. Raine, Cambridge, United Kingdom H. Gordon, London, United Kingdom 6: Are there situations where guidelines are not appropriate? 15:15 - 15:30 S. Bonovas, Milan, Italy J. Torres, Loures, Portugal 7: Are there situations where GRADE fails us? Is there still a role for Oxford evidence? 15:30 - 15:45 T. Lytras, Athens, Greece H. Gordon, London, United Kingdom 8: Do guidelines prevent patient-centred care? 15:45 - 16:00 H. Gordon, London, United Kingdom S. Jäghult, Stockholm, Sweden 46 16th Congress of ECCO - European Crohn‘s and Colitis Organisation July 2-3 & 8-10, 2021 • Virtual 47 Industry sponsored satellite symposia Paid advertisement by Dr. Falk Pharma Industry sponsored satellite symposia Industry sponsored satellite symposia organised by pharmaceutical companies are open to all congress participants. The programmes of symposia are not affiliated with ECCO and sponsors hold responsibility for the content of their respective programmes.
Industry sponsored satellite symposia – Scientific programme Thursday, July 8, 2021 Satellite Symposium 1a Organiser: AbbVie Meeting room: Virtual Plenary Hall Leaping into the future: exploring IL-23 inhibition for CD management INNOVATION 11:00 - 12:00 R. Panaccione, Calgary, Canada G. D‘Haens, Amsterdam, The Netherlands DRIVES EVERYTHING Opening, Welcome and Introduction 11:00 - 11:05 R. Panaccione, Calgary, Canada Dr. Falk Pharma – the experts in Current goals and gaps in CD management 11:05 - 11:20 G. D‘Haens, Amsterdam, The Netherlands digestive and metabolic medicine Advancing IL23i as a new therapeutic class: new Ph 11:20 - 11:35 3 data from a new MoA Innovation drives everything we do. As special- R. Panaccione, Calgary, Canada ists in digestive and metabolic medicine, we The next big leap in CD treatment? 11:35 - 11:50 G. D‘Haens, Amsterdam, The Netherlands bring physicians, scientists, and patients together Faculty discussion and Q&A to develop new and powerful approaches to 11:50 - 12:00 R. Panaccione, Calgary, Canada patient care. We continuously listen to your G. D‘Haens, Amsterdam, The Netherlands needs and respond with treatment solutions that https://www.ema.europa.eu/en/medicines/human/EPAR/ humira provide real improvement to patients’ health and https://www.ema.europa.eu/en/medicines/human/EPAR/ well-being. As a research-based family business Product remicade characteristics https://www.ema.europa.eu/en/medicines/human/EPAR/ with global presence, we are investing in trials stelara in IBD, PSC, NASH and Celiac Disease with new https://www.ema.europa.eu/en/medicines/human/EPAR/ entyvio compounds. Our aim is to help transform clinical practice, one life-changing discovery at a time.
Together we know more. Together we do more. Dr. Falk Pharma GmbH Leinenweberstr. 5 | 79108 Freiburg | Germany www.drfalkpharma.com 48 16th Congress of ECCO - European Crohn‘s and Colitis Organisation Industry sponsored satellite symposia Industry sponsored satellite symposia
Satellite Symposium 1b Satellite Symposium 2a Organiser: Janssen Organiser: Takeda Meeting room: Virtual Room 1 Meeting room: Virtual Plenary Hall Early choices in CD care Targeting progression of Crohn’s disease to improve 11:00 - 12:00 I. Dotan, Tel Aviv, Israel 17:55 - 18:55 patient outcomes Welcome and introduction Opening, welcome and introductions 11:00 - 11:05 I. Dotan, Tel Aviv, Israel 17:55 - 17:58 I. Dotan, Petah Tikva, Israel State-of-the-art management of CD Optimizing treatment approaches to hinder disease 11:05 - 11:25 A. Dignass, Frankfurt, Germany 17:58 - 18:08 progression in patients with Crohn’s disease Shining a light on individual management of CD T. Raine, Cambridge, United Kingdom 11:25 - 11:45 M. Allez, Paris, France An evidence-based approach to changing the Addressing practical questions to improve your 18:08 - 18:25 clinical course in Crohn’s disease daily clinic I. Dotan, Petah Tikva, Israel 11:45 - 11:55 I. Dotan, Tel Aviv, Israel Treating moderate-to-severe Crohn’s disease: M. Allez, Paris, France 18:25 - 18:40 Lessons from clinical practice A. Dignass, Frankfurt, Germany R. Panaccione, Calgary, Canada Summary and close Panel Discussion / Q&A 11:55 - 12:00 I. Dotan, Tel Aviv, Israel 18:40 - 18:55 All faculty Product https://www.ema.europa.eu/en/documents/product- characteristics information/entyvio-epar-product-information_en.pdf Satellite Symposium 1c Organiser: Amgen Meeting room: Virtual Room 2 Satellite Symposium 2b Artificial intelligence – the piece of the puzzle to Organiser: Galapagos 11:00 - 12:00 transform IBD management Meeting room: Virtual Room 1 Welcome 17:55 - 18:55 We see what UC: Time for a holistic approach to 11:00 - 11:05 G. Fiorino, Rozzano, Italy remission Early intervention – Fitting the referral and 17:55 - 18:00 Welcome and Introductions 11:05 - 11:15 diagnosis pieces together A. Dignass, Frankfurt, Germany (Chair) G. Fiorino, Rozzano, Italy Eyes on the prize: defining what holistically What can AI bring to the patient management approaching remission means for our patients puzzle? 18:00 - 18:15 A. Dignass, Frankfurt, Germany 11:15 - 11:30 E. Louis, Liège, Belgium in discussion with C. Lees, Edinburgh, United Kingdom G. Fiorino, Rozzano, Italy M. Fumery, Amiens, France The coming of age of personalised medicine in the Looking deeper: contextualising treatment 11:30 - 11:45 IBD clinic 18:15 - 18:35 decisions from the perspective of holistic health W. Reinisch, Vienna, Austria C. Lees, Edinburgh, United Kingdom Panel Q&A and meeting close The long view: examining key tactics to optimise G. Fiorino, Rozzano, Italy 18:35 - 18:45 patient care in an adapting world 11:45 - 12:00 E. Louis, Liège, Belgium M. Fumery, Amiens, France W. Reinisch, Vienna, Austria Live Q&A A. Dignass, Frankfurt, Germany 18:45 - 18:55 C. Lees, Edinburgh, United Kingdom M. Fumery, Amiens, France
50 16th Congress of ECCO - European Crohn‘s and Colitis Organisation July 2-3 & 8-10, 2021 • Virtual 51 Industry sponsored satellite symposia
Satellite Symposium 2c Organiser: Eli Lilly Meeting room: Virtual Room 2 Identifying Bowel Urgency in Patients With 17:55 - 18:55 Ulcerative Colitis: The Need for Speed Welcome and introduction UR-CARE 17:55 - 18:00 M. Dubinsky, New York, United States Why Bowel Urgency Matters 18:00 - 18:15 M. Dubinsky, New York, United States Online Opening Up About Bowel Urgency: A Patient’s Perspective 18:15 - 18:25 M. Dubinsky, New York, United States now! Emily Morgan, Shelby, United States Sensitive Strategies for Embarrassing Symptoms 18:25 - 18:45 S. Ghosh, Cork, Ireland “Ask the Faculty” and Take-Home Messages 18:45 - 18:55 M. Dubinsky, New York, United States Friday, July 9, 2021 Satellite Symposium 3a Organiser: Takeda Meeting room: Virtual Plenary Hall Breaking the vicious cycle of Crohn’s perianal 07:15 - 08:15 fistulas – a multidisciplinary team approach Opening, welcome and introductions 07:15 - 07:20 A. Spinelli, Rozzano, Italy Redefining treatment success for patients with Crohn’s perianal fistulas – Perspectives of a 07:20 - 07:40 gastroenterologist P. Michetti, Lausanne, Switzerland Redefining treatment success for patients with Crohn’s perianal fistulas – Perspectives of a The IBD Database for your patient 07:40 - 08:05 colorectal surgeon A. Spinelli, Rozzano, Italy records and your research studies 08:05 - 08:15 Panel Discussion / Q&A All faculty What to expect: Product https://www.ema.europa.eu/en/documents/product- • Comprehensive registry • Retro- & prospective data characteristics information/alofisel-epar-product-information_en.pdf capturing demographics, collection and evaluation environmental factors, • Autonomous data clinical characteristics, management offered to examinations and study groups therapeutic interventions • Precise data ownership in IBD rules
Scan and visit www.ecco-ibd.eu/ur-care 52 16th Congress of ECCO - European Crohn‘s and Colitis Organisation July 2-3 & 8-10, 2021 • Virtual 53 Industry sponsored satellite symposia
Satellite Symposium 3b Organiser: AbbVie Meeting room: Virtual Room 1 Leaping into the future: exploring IL-23 inhibition for CD management 07:15 - 08:15 R. Panaccione, Calgary, Canada G. D‘Haens, Amsterdam, The Netherlands Opening, Welcome and Introduction 07:15 - 07:20 R. Panaccione, Calgary, Canada Current goals and gaps in CD management 07:20 - 07:35 G. D‘Haens, Amsterdam, The Netherlands Advancing IL23i as a new therapeutic class: new Ph 07:35 - 07:50 3 data from a new MoA R. Panaccione, Calgary, Canada The next big leap in CD treatment? 07:50 - 08:05 G. D‘Haens, Amsterdam, The Netherlands Nestlé Health Science Satellite Symposium | ECCO’21 Virtual Congress Faculty discussion and Q&A 08:05 - 08:15 R. Panaccione, Calgary, Canada G. D‘Haens, Amsterdam, The Netherlands https://www.ema.europa.eu/en/medicines/human/EPAR/ Diet in the Treatment humira https://www.ema.europa.eu/en/medicines/human/EPAR/ Product remicade characteristics https://www.ema.europa.eu/en/medicines/human/EPAR/ stelara Paradigm of Crohn’s https://www.ema.europa.eu/en/medicines/human/EPAR/ entyvio
Satellite Symposium 3c Disease: New Evidence, Organiser: Nestlé Health Science Meeting room: Virtual Room 2 Diet in the Treatment Paradigm of Crohn’s Disease: 07:15 - 08:15 New Evidence, New Strategies New Strategies Welcome & Introduction to the symposium 07:15 - 07:25 F. Carbonnel, Paris, France 07:25 - 07:45 From evidence to clinical strategies with CDED th A. Levine, Holon, Israel Friday 9 July 2021 Crohn’s disease exclusion diet in adults – an 07:45 - 08:05 addition to the therapeutic toolbox N. Maharshak, Tel Aviv, Israel 07:15 – 08:15 am CET Q&A F. Carbonnel, Paris, France 08:05 - 08:15 A. Levine, Holon, Israel N. Maharshak, Tel Aviv, Israel To join go to Satellite Symposia Overview
Paid advertisement by
This programme is not 54 16th Congress of ECCO - European Crohn‘s and Colitis Organisation affiliated with ECCO July 2-3 & 8-10, 2021 • Virtual 55 Industry sponsored satellite symposia Industry sponsored satellite symposia
Lunchtime Satellite Symposium LS1 Lunchtime Satellite Symposium LS2 Organiser: AbbVie Organiser: Arena Pharmaceuticals Meeting room: Virtual Plenary Hall Meeting room: Virtual Room 1 Next Generation Inhibition of JAK Signalling: Keeping on Track in UC: Navigating Treatment Aspiring for New Depths in UC Outcomes Decisions with Patients Considering Advanced 12:10 - 12:50 J. Colombel, New York, United States 12:10 - 12:50 Therapy J. Lindsay, London, United Kingdom S. Vermeire, Leuven, Belgium D. Rubin, Chicago, United States 12:10 - 12:15 Opening, Welcome & Introduction J. Colombel, New York, United States 12:10 - 12:12 Welcome Current Unmet Need & Evolution of Therapeutic D. Rubin, Chicago, United States Goals in Ulcerative Colitis- What does this mean in Embarking on the journey: Setting the path to 12:15 - 12:30 daily practice? 12:12 - 12:24 sustained disease control J. Lindsay, London, United Kingdom S. Vermeire, Leuven, Belgium Next generation JAK Inhibition – Emerging data Discussion 12:30 - 12:45 from recent Ph3 clinical studies 12:24 - 12:30 S. Vermeire, Leuven, Belgium J. Colombel, New York, United States D. Rubin, Chicago, United States Cross Indication Considerations- What Staying the course: Considerations when Gastroenterologists can learn from other 12:30 - 12:42 transitioning to advanced therapy 12:45 - 12:50 specialities D. Rubin, Chicago, United States J. Lindsay, London, United Kingdom Discussion https://www.ema.europa.eu/en/medicines/human/EPAR/ 12:42 - 12:48 S. Vermeire, Leuven, Belgium remicade D. Rubin, Chicago, United States Product https://www.ema.europa.eu/en/medicines/human/EPAR/ characteristics xeljanz 12:48 - 12:50 Summary and close https://www.ema.europa.eu/en/medicines/human/EPAR/ S. Vermeire, Leuven, Belgium entyvio https://www.ema.europa.eu/en/medicines/human/EPAR/ entyvio https://www.ema.europa.eu/en/medicines/human/EPAR/ remicade Product https://www.ema.europa.eu/en/medicines/human/EPAR/ characteristics humira https://www.ema.europa.eu/en/medicines/human/EPAR/ stelara https://www.ema.europa.eu/en/medicines/human/EPAR/ xeljanz
56 16th Congress of ECCO - European Crohn‘s and Colitis Organisation July 2-3 & 8-10, 2021 • Virtual 57 Industry sponsored satellite symposia Industry sponsored satellite symposia
Lunchtime Satellite Symposium LS3 Satellite Symposium 4a Organiser: Celltrion Healthcare Organiser: Takeda Meeting room: Virtual Room 2 Meeting room: Virtual Planary Hall Navigating the Evolving Anti-TNF Therapy for Pushing the boundaries in the management of 12:10 - 12:50 Inflammatory Bowel Disease 17:55 - 18:55 Ulcerative Colitis: Is “disease clearance” possible? G. D’Haens, Amsterdam, The Netherlands 17:55 - 17:57 Opening, welcome and introductions 12:10 - 12:13 Opening remarks S. Ghosh, Cork, Ireland G. D’Haens, Amsterdam, The Netherlands Challenging perceptions in UC: How could early Recent Progress in Anti-TNF Therapies for 17:57 - 18:10 intervention optimize patient outcomes? 12:13 - 12:23 Inflammatory Bowel Disease P. Bossuyt, Bonheiden, Belgium G. D’Haens, Amsterdam, The Netherlands Evolving treatment goals in UC: Where are we Switching from IV to SC Infliximab in Inflammatory 18:10 - 18:25 heading? S. Ghosh, Cork, Ireland 12:23 - 12:38 Bowel Disease Patients in Real World Setting C. Probert, Liverpool, United Kingdom “Disease clearance” as a treatment goal in UC: P. Smith, Liverpool, United Kingdom 18:25 - 18:40 Concept or reality? High-concentration and Low-volume of S. Vermeire, Leuven, Belgium 12:38 - 12:48 Adalimumab Biosimilar Panel discussion / Q&A M. Lukas, Prague, Czech Republic 18:40 - 18:55 All faculty 12:48 - 12:50 Summary & Closing Remarks Product https://www.ema.europa.eu/en/documents/product- G. D’Haens, Amsterdam, The Netherlands characteristics information/entyvio-epar-product-information_en.pdf https://www.ema.europa.eu/en/documents/product- Product information/remsima-epar-product-information_en.pdf characteristics https://www.ema.europa.eu/en/documents/product- Satellite Symposium 4b information/yuflyma-epar-product-information_en.pdf Organiser: Pfizer Meeting room: Virtual Room 1 Latest Insights on the Impact of JAK Inhibitors in the Lunchtime Satellite Symposium LS4 Evolving Treatment Paradigm in UC Organiser: Bristol Myers Squibb 17:55 - 18:55 D. Rubin, Chicago, United States Meeting room: Virtual Room 3 P. Irving, London, United Kingdom 12:10 - 12:50 Evolving the future of UC management: A focus on Welcome and introduction improving long-term outcomes 17:55–18:00 D. Rubin, Chicago, United States Welcome and introductions Part 1: Tofacitinib: From the Laboratory Bench to 12:10-12:13 G. Rogler, Zurich, Switzerland 18:00–18:20 Clinical Trials Evolution of targeting inflammation in the D. Rubin, Chicago, United States 12:13-12:28 management of UC P. Irving, London, United Kingdom R. Atreya, Erlangen, Germany Part 2: Tofacitinib Benefit–Risk Profile: What Have UC treatment targets: 18:20–18:40 We Learned From Recent Clinical and Real-world Achieving corticosteroid-free remission Data? 12:28-12:48 Achieving mucosal healing: endoscopic and P. Irving, London, United Kingdom histologic improvement Part 3: What Is the Role of Tofacitinib in the UC G. Rogler, Zurich, Switzerland 18:40–18:45 Treatment Paradigm, and What Does the Future Concluding remarks Hold? 12:48-12:50 R. Atreya, Erlangen, Germany D. Rubin, Chicago, United States Q&A 18:45–18:55 D. Rubin, Chicago, United States P. Irving, London, United Kingdom Product https://www.ema.europa.eu/en/medicines/human/EPAR/ characteristics xeljanz#product-information-section
58 16th Congress of ECCO - European Crohn‘s and Colitis Organisation July 2-3 & 8-10, 2021 • Virtual 59 Industry sponsored satellite symposia Industry sponsored satellite symposia
Saturday, July 10, 2021 Satellite Symposium 4c Organiser: Fresenius Kabi Satellite Symposium 5a Meeting room: Virtual Room 2 Organiser: Galapagos Meeting room: Virtual Plenary Hall Microbiota, Nutrition and Inflammation : An 17:55 - 18:55 opening towards personalized IBD treatment 07:15 - 08:15 New horizons in UC management: Exploring the P. Seksik, Paris, France place for novel treatment options Welcome and introduction 07:15 - 07:20 Welcome and introduction 17:55 – 18:00 P. Seksik, Paris, France A. Armuzzi, Rome, Italy (Chair) Interpreting the evidence between Nutrition and Novel methods of targeting inflammation in UC: 18:00 – 18:15 IBD 07:20 - 07:35 why, what and how? J. Lindsay, London, United Kingdom T. Raine, Cambridge, United Kingdom How to manipulate microbiota to control How will we choose? Biologics and small molecules 18:15 – 18:30 inflammation 07:35 - 07:55 in the future of UC care - Discussion P. Seksik, Paris, France A. Armuzzi, Rome, Italy T. Raine, Cambridge, United Kingdom Personalizing IBD treatment, predicting response 18:30 – 18:45 to anti-TNF Choosing the right treatment for the right patient - R. Atreya, Erlangen, Germany Case presentation and discussion 07:55 - 08:05 A. Armuzzi, Rome, Italy Conclusion and outlook thoughts T. Raine, Cambridge, United Kingdom 18:45 – 18:55 P. Seksik, Paris, France Discussion and Q&A 08:05 - 08:15 A. Armuzzi, Rome, Italy T. Raine, Cambridge, United Kingdom
Satellite Symposium 5b Organiser: Pfizer Meeting room: Virtual Room 1 Latest Insights on the Impact of JAK Inhibitors in the Evolving Treatment Paradigm in UC 07:15 - 08:15 D. T. Rubin, Chicago, United States P. Irving, London, United Kingdom Welcome and introduction 07:15–07:20 D. Rubin, Chicago, United States Part 1: Tofacitinib: From the Laboratory Bench to Clinical Trials 07:20–07:40 D. Rubin, Chicago, United States P. Irving, London, United Kingdom Part 2: Tofacitinib Benefit–Risk Profile: What Have We Learned From Recent Clinical and Real-world 07:40–08:00 Data? P. Irving, London, United Kingdom Part 3: What Is the Role of Tofacitinib in the UC Treatment Paradigm, and What Does the Future 08:00–08:05 Hold? D. Rubin, Chicago, United States Q&A 08:05–08:15 P. Irving, London, United Kingdom Product https://www.ema.europa.eu/en/medicines/human/EPAR/ characteristics xeljanz#product-information-section
60 16th Congress of ECCO - European Crohn‘s and Colitis Organisation July 2-3 & 8-10, 2021 • Virtual 61 Industry sponsored satellite symposia Industry sponsored satellite symposia
Satellite Symposium 5c Lunchtime Satellite Symposium LS5 Organiser: Arena Pharmaceuticals Organiser: AbbVie Meeting room: Virtual Room 2 Meeting room: Virtual Plenary Hall Keeping on Track in UC: Navigating Treatment Next Generation Inhibition of JAK Signalling: Decisions with Patients Considering Advanced Aspiring for New Depths in UC Outcomes 07:35- 08:15 Therapy 12:10 - 12:50 J. Colombel, New York, United States S. Vermeire, Leuven, Belgium J. Lindsay, London, United Kingdom D. T. Rubin, Chicago, United States Opening, Welcome & Introduction Welcome 12:10 - 12:15 J. Colombel, New York, United States 07:35 - 07:37 D. Rubin, Chicago, United States Current Unmet Need & Evolution of Therapeutic Embarking on the journey: Setting the path to Goals in Ulcerative Colitis- What does this mean in 07:37 - 07:49 sustained disease control 12:15 - 12:30 daily practice? S. Vermeire, Leuven, Belgium J. Lindsay, London, United Kingdom Discussion Next generation JAK Inhibition – Emerging data 07:49 - 07:55 S. Vermeire, Leuven, Belgium 12:30 - 12:45 from recent Ph3 clinical studies D. Rubin, Chicago, United States J. Colombel, New York, United States Staying the course: Considerations when Cross Indication Considerations- What 07:55 - 08:07 transitioning to advanced therapy Gastroenterologists can learn from other D. Rubin, Chicago, United States 12:45 - 12:50 specialities Discussion J. Lindsay, London, United Kingdom 08:07 - 08:13 S. Vermeire, Leuven, Belgium https://www.ema.europa.eu/en/medicines/human/EPAR/ D. Rubin, Chicago, United States remicade Summary and close Product https://www.ema.europa.eu/en/medicines/human/EPAR/ 08:13 - 08:15 S. Vermeire, Leuven, Belgium characteristics xeljanz https://www.ema.europa.eu/en/medicines/human/EPAR/ https://www.ema.europa.eu/en/medicines/human/EPAR/ entyvio entyvio https://www.ema.europa.eu/en/medicines/human/EPAR/ remicade Lunchtime Satellite Symposium LS6 Product https://www.ema.europa.eu/en/medicines/human/EPAR/ Organiser: Takeda characteristics humira Meeting room: Virtual Room 1 https://www.ema.europa.eu/en/medicines/human/EPAR/ stelara 12:10 - 12:50 IBD in COVID 19 pandemic times: Emerging https://www.ema.europa.eu/en/medicines/human/EPAR/ evidence from clinical practice xeljanz Opening, Welcome & Introduction 12:10 - 12:15 R. Ungaro, New York, United States The impact of COVID 19 on IBD patients: lessons 12:15 - 12:30 from SECURE-IBD registry R. Ungaro, New York, United States Anti-SARS-CoV-2 antibody responses and IBD 12:30 - 12:45 medications: results from the Clarity-IBD study T. Ahmed, Exeter, United Kingdom Panel discussion / Q&A 12:45 - 12:50 All faculty Product https://www.ema.europa.eu/en/documents/product- characteristics information/entyvio-epar-product-information_en.pdf
62 16th Congress of ECCO - European Crohn‘s and Colitis Organisation July 2-3 & 8-10, 2021 • Virtual 63 Industry sponsored satellite symposia Industry exhibition
Industry sponsored satellite symposia – Educational programme Industry exhibition Saturday, July 3, 2021– N-ECCO Network Meeting Satellite Symposium Organiser: Takeda The exhibition opens on June 28, 2021 and will remain Meeting room: Virtual Room 6 available until October 31, 2021. The Silver Storm is here! A candid conversation on geriatric care and IBD 12:25 - 13:25 L. White, Oxford, United Kingdom List of exhibitors & sponsors A. Sturm, Berlin, Germany Company A silver storm! Why focus on elderly patients with IBD? Premium Booth Ageing or elderly onset: Know your phenotypes! AbbVie Commercial More than just a number: Holistic approaches for AbbVie Medical Fairs elderly patients with IBD Arena Pharmaceuticals Live Q&A Product https://www.ema.europa.eu/en/documents/product- Bristol-Myers Squibb characteristics information/entyvio-epar-product-information_en.pdf Eli Lilly and Company Fresenius Kabi Saturday, July 3, 2021 – S-ECCO IBD Masterclass Galapagos Satellite Symposium Organiser: Takeda Janssen Meeting room: Virtual Room 4 Janssen Medical How long is too long? A fireside chat exploring goal Pfizer 13:30 - 14:30 setting in complex Crohn’s perianal fistulas P. Kienle, Mannheim, Germany Takeda H. Guadalajara, Madrid, Spain Blurred lines: The journey from acute to long-term Advanced Booth goals Amgen Can a solution become a problem? The role and Biogen impact of long-term seton use Fistula healing: an attainable long-term goal Dr. Falk Pharma Live Q&A Standard Booth Product https://www.ema.europa.eu/en/documents/product- AstraZeneca characteristics information/alofisel-epar-product-information_en.pdf Bühlmann Laboratories Kaleido Nestlé Health Science UEG United European Gastroenterology GmbH
64 16th Congress of ECCO - European Crohn‘s and Colitis Organisation July 2-3 & 8-10, 2021 • Virtual 65 Corporate sponsors Corporate sponsors
Corporate sponsors (as of June 24, 2021) ECCO gratefully acknowledges the support of the following ECCO Corporate Members:
66 16th Congress of ECCO - European Crohn‘s and Colitis Organisation July 2-3 & 8-10, 2021 • Virtual 67 Imprint
Inflammatory Bowel Diseases Announcement 2022
© SO/ Vienna - Gilles Trillard 17th Congress of ECCO Reed Messe Wien February 16-19, 2022
Imprint Publisher ECCO – European Crohn’s and Colitis Organisation OCEAiN – Organisation, Congress, Emotion, Association, iNnovation GmbH Ungargasse 6/13, 1030 Vienna, Austria Phone: +43-(0)1-710 22 42 Fax: +43-(0)1-710 22 42-001 E-Mail: [email protected] Web: www.ecco-ibd.eu